SAB Biotherapeutics News - SABS

Company Name	Stock Ticker Symbol	Market	Type
SAB Biotherapeutics Inc	SABS	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	4.39	04:29:21

Open Price	Low Price	High Price	Close Price	Prev Close
				4.39

more quote information »

Recent News

Date	Time	Source	Heading
4/22/2024	8:49	IHNW	FeaturedCannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California
4/16/2024	07:15	GLOBE	SAB Biotherapeutics Provides SAB-142 Trial Update
4/08/2024	07:15	GLOBE	SAB Biotherapeutics to Present at INNODIA Annual Meeting
4/04/2024	07:15	GLOBE	SAB Biotherapeutics to Present at the Needham Virtual..
3/29/2024	07:15	GLOBE	SAB Biotherapeutics Reports Full Year 2023 Operating and..
3/25/2024	10:15	GLOBE	SAB Biotherapeutics Announces Clinical Partnership with..
3/08/2024	16:30	EDGAR2	Form 8-K - Current report
2/23/2024	16:55	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	16:45	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	08:00	GLOBE	SAB Biotherapeutics to Present at the BIO CEO & Investor..
2/08/2024	08:00	GLOBE	SAB Biotherapeutics to Present at the Oppenheimer..
2/02/2024	07:53	EDGAR2	Form 8-K - Current report
2/02/2024	07:30	GLOBE	SAB Biotherapeutics Announces Executive Leadership Change
1/26/2024	16:15	EDGAR2	Form 8-K - Current report
1/26/2024	16:00	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
1/25/2024	17:00	EDGAR2	Form 8-K - Current report
1/23/2024	17:58	GLOBE	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
1/19/2024	16:21	EDGAR2	Form 8-K - Current report
1/03/2024	09:00	EDGAR2	Form 8-K - Current report
1/02/2024	16:30	GLOBE	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
12/18/2023	09:34	EDGAR2	Form DEF 14A - Other definitive proxy statements
12/08/2023	17:26	EDGAR2	Form PRE 14A - Other preliminary proxy statements
11/30/2023	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/29/2023	07:40	EDGAR2	Form 8-K - Current report
11/29/2023	07:30	GLOBE	SAB Biotherapeutics Announces Commencement of the HUMAN..
11/29/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
11/28/2023	16:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/28/2023	16:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/22/2023	16:45	EDGAR2	Form 8-K - Current report
11/20/2023	17:00	EDGAR2	Form 8-K - Current report
11/20/2023	16:45	EDGAR2	Form S-3/A - Registration statement under Securities Act of..
11/20/2023	07:30	GLOBE	SAB Biotherapeutics Appoints Katie Ellias to the Board of..
11/14/2023	19:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/14/2023	07:30	GLOBE	SAB Biotherapeutics Announces Completion of $67.1 Million..
11/14/2023	07:15	GLOBE	SAB Biotherapeutics Announces Q3 2023 Financial Results and..
11/13/2023	16:48	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/2023	07:30	GLOBE	SAB Biotherapeutics to Present at Piper Sandler Healthcare..
11/03/2023	17:00	EDGAR2	Form S-3 - Registration statement under Securities Act of..
11/03/2023	16:50	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/30/2023	17:00	EDGAR2	Form DEF 14A - Other definitive proxy statements
10/27/2023	17:00	EDGAR2	Form 8-K - Current report
10/24/2023	17:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/24/2023	07:30	GLOBE	SAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
10/20/2023	16:30	EDGAR2	Form PRE 14A - Other preliminary proxy statements
10/19/2023	07:30	GLOBE	SAB Biotherapeutics Receives Australian Approval to Commence..
10/05/2023	07:30	GLOBE	SAB Biotherapeutics Approves Appointment of Andrew Moin to..
10/02/2023	16:10	EDGAR2	Form 8-K - Current report
10/02/2023	07:30	GLOBE	SAB Biotherapeutics Announces Private Placement of up to..
8/21/2023	16:15	EDGAR2	Form S-3 - Registration statement under Securities Act of..
8/21/2023	08:30	GLOBE	SAB Biotherapeutics Provides Company Update for Q2..
8/21/2023	08:25	EDGAR2	Form 8-K - Current report